SCHEMBL10249255

SCHEMBL10249255

COCCc1cnccc1-c1nc2cc(C)cnc2n1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE10A Q9Y233 3/20 0.37
AKT1 P31749 3/20 0.35
AOC3 Q16853 1/20 0.35
AKT2 P31751 2/20 0.34
BRD4 O60885 1/20 0.34
PDE2A O00408 1/20 0.33
PADI4 Q9UM07 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
NFATC1 O95644 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10284539 0.86 POLB (0.42) POLBSMN1; SMN2PDE10APDE2APADI4
SCHEMBL10249224 0.84 PDE10A (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249030 0.84 POLB (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249153 0.81 SMN1; SMN2 (0.36) POLBSMN1; SMN2PDE10AAKT1AOC3
SCHEMBL4451502 0.80 PDE10A (0.35) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249083 0.80 POLB (0.50) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL4403186 0.79 PDE10A (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10248934 0.78 PDE1A (0.39) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249089 0.78 POLB (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249027 0.77 MAPT (0.43) POLBSMN1; SMN2PDE10AAKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885PDE10A 4112/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885PDE10A 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.